Northway Biotech (formerly Northway Biotechpharma), a biopharma contract development and manufacturing organization (CDMO), has opened its new 30,000-square-foot process development and current good manufacturing practices (cGMP) site in the Greater Boston area (Waltham, MA).
From cell line development to cGMP DS manufacturing and aseptic filling, the facility is expected to provide end-to-end services for biologics microbial and mammalian-based biologics.
Currently, the new site has fully established process, analytical method development and quality control labs supporting local and international customer projects since summer 2020. The cGMP biomanufacturing suite will contain 500 L microbial and 2,000 L mammalian bioreactors which will be operational in the fourth quarter, representing a capital investment program worth $40 million.
The post Northway Biotech unveils new 30,000 square-foot biopharm manufacturing facility appeared first on Pharmaceutical Commerce.
